Bayer HealthCare and Regeneron Pharmaceuticals have reported positive results from the Phase III VIVID-DME trial of Eylea (aflibercept) injection for treatment of diabetic macular edema (DME).

In the VIVID-DME trial, patients were randomised to receive either Eylea injection into the eye every month (n=136), Eylea injection every two months (n=135), or the comparator treatment of laser photocoagulation (n=132).

The trial showed that Eylea 2mg in both treatment groups showed a sustained improvement from baseline in best corrected visual acuity (BCVA) at week 100, compared with laser photocoagulation.

Patients receiving Eylea injection every month had a mean gain from baseline in BCVA of 11.4 letters, while those receiving it every two months had a mean gain from baseline in BCVA of 9.4 letters.

"The trial showed that Eylea 2mg in both treatment groups showed a sustained improvement from baseline in best corrected visual acuity (BCVA) at week 100, compared with laser photocoagulation."

Individuals in the laser photocoagulation treatment group had a mean change from baseline in BCVA of 0.7 letters.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

See Also:

In addition, 31.1% of patients receiving Eylea injection 2mg every two months achieved an increase of greater than or equal to 15 letters, a gain of three lines from baseline as one of the endpoints compared to the laser treatment group with only 12% achieving a similar gain.

In the trial, Eylea had a similar overall incidence of adverse events (AEs), ocular serious AEs, and non-ocular serious AEs across the Eylea treatment groups and the laser control group.

Regeneron chief scientific officer and Regeneron Laboratories president George Yancopoulos said: "These data showed that treatment with Eylea in this trial improved vision and maintained the improvement over two years in patients with diabetic macular edema."

In the US, EYLEA was approved for the treatment of neovascular (wet) age-related macular degeneration (AMD) in November 2011 and for macular edema following central retinal vein occlusion (CRVO) in September 2012.

The drug has also been approved in the EU and other countries for use in wet AMD and Macular Edema following CRVO.

Bayer and Regeneron are collaborating on the global development of Eylea, with Regeneron maintaining exclusive rights of the drug in the US and Bayer having exclusive marketing rights outside the US.